Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: In vitro and in vivo assessment

Blood

Volumn 104, Issue 5, 2004, Pages 1450-1458

  Yuan, Jun ^a   Lovejoy, David B ^a   Richardson, Des R ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 1 NAPHTHYLALDEHYDE ISONICOTINOYLHYDRAZONE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; CASPASE 3; CYTOCHROME C; CYTOTOXIC AGENT; DEFEROXAMINE; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; DI 2 PYRIDYLTHIOSEMICARBAZONE DERIVATIVE; DOXORUBICIN; HOLOCYTOCHROME C; HYDRAZONE DERIVATIVE; IRON 59; IRON CHELATING AGENT; PYRIDINE DERIVATIVE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVATION; FEMALE; FIBROBLAST; HEMATOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; IRON CHELATION; LUNG CANCER; MALE; MOUSE; NEUROEPITHELIOMA; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 4444248453     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-03-0868     Document Type: Article

References (84)

1. Le NTV, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta. 2002;1603:31-46.
2. Blatt J, Stitely S. Antineuroblastoma activity of desferrioxamine in human cell lines. Cancer Res. 1987;47:1749-1750.
3. Estrov Z, Tawa A, Wang X-H, et al. In vivo and in vitro effects of desferrioxamine in neonatal acute leukemia. Blood. 1987;69:757-761.
4. Becton DL, Bryles P. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res. 1988;48:7189-7192.
5. Donfrancesco A, Deb G, Dominici C, et al. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. 1990;50:4929-4930.
6. Finch RA, Liu M-C, Grill SP, et al. Triapine (3-aminopyridine-2- carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol. 2000;59:983-991.
7. Lovejoy DB, Richardson DR. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate high anti-proliferative activity that is selective for tumor cells. Blood. 2002;100:666-676.
8. Becker E, Lovejoy DB, Greer JM, Watts RN, Richardson DR. Novel aroylhydrazone iron chelators differ in their iron chelation efficacy and antiproliferative activity: identification of a new class of potential anti-proliferative agents. Br J Pharmacol. 2003;138:819-830.
9. Chaston TB, Lovejoy DB, Watts RN, Richardson DR. Examination of the anti-proliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared to desferrioxamine and the potent PIH analogue 311. Clin Cancer Res. 2003;9:402-414.
10. Hershko C. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillière's Clin Haematol. 1994;7:965-1000.
11. Lovejoy DB, Richardson DR. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem. 2003;10:1065-1078.
12. Larrick JW, Cresswell P. Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J Supramol Struct. 1979;11:579-586.
13. Richardson DR, Baker E. The uptake of iron and transferrin by the human melanoma cell. Biochim Biophys Acta. 1990;1053:1-12.
14. Richardson DR, Baker E. Two mechanisms of iron uptake from transferrin by melanoma cells: the effect of desferrioxamine and ferric ammonium citrate. J Biol Chem. 1992;267:13972-13979.
15. Trinder D, Zak O, Aisen P. Transferrin receptor-independent uptake of diferric transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology. 1996;23:1512-1520.
16. Thelander L, Reichard P. The reduction of ribonucleotides. Annu Rev Biochem. 1979;48:133-158.
17. Nyholm S, Mann GJ, Johansson AG, Bergeron RJ, Graslund A, Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem. 1993;268:26200-26205.
18. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem. 1996;271:20291-20299.
19. Witt L, Yap T, Blakely RL. Regulation of ribonucleotide reductase activity and its possible exploitation in chemotherapy. Adv Enzyme Regul. 1979;17:157-171.
20. Takeda E, Weber G. Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci. 1981;28:1007-1014.
21. Green DA, Antholine WE, Richardson DR, Chitambar CR. Ribonucleotide reductase as a preferential target for the inhibition of leukemic cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class. Clin Cancer Res. 2001;7:3574-3579.
22. Richardson DR, Ponka P, Baker E. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res. 1994;54:685-689.
23. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents. Blood. 1995;86:4295-4306.
24. Richardson DR, Milnes K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood. 1997;89:3025-3038.
25. Torti SV, Torti FM, Whitman SP, Brechbiel MW, Park G, Planalp RP. Tumor cell cytotoxicity of a novel metal chelator. Blood. 1998;92:1384-1389.
26. Rakba N, Loyer P, Gilot D, et al. Anti-proliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis. 2000;21:943-951.
27. Simonart T, Degraef C, Andrei G, et al. Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J Invest Dermatol. 2000;115:893-900.
28. Kicic A, Chua AC, Baker B. Desferrithiocin is a more potent antineoplastic agent than desferrioxamine. Br J Pharmacol. 2002;135:1393-1402.
29. Wang F, Elliott RL, Head JF. Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. Anticancer Res. 1999;19:445-450.
30. Kemp JD, Cardillo T, Stewart BC, et al. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Res. 1995;55:3817-3824.
31. Dezza L, Cazzola M, Danova M, et al. Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies. Leukemia. 1989;3:104-107.
32. Donfrancesco A, Deb G, Dominici C, et al. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECat): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol. 1992;15:319-322.
33. Donfrancesco A, De Bernardi B, Carli M, et al. Deferoxamine (D) followed by cytoxan (C), etoposide (E), carboplatin (Ca), thio-TEPA (T), induction regimen in advanced neuroblastoma. Eur J Cancer. 1995;31A:612-615.
34. Giles FJ, Fracasso PM, Kantarjian HM, et al. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003;27:1077-1083.
35. Feun L, Modiano M, Lee K, et al. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol. 2002;50:223-229.
36. Krakoff IH, Etcubanas E, Tan C, Mayer K, Bethune V, Burchenai JH. Clinical trial of 5-hydroxypicolinaldehyde thiosemicarbazone (5-HP: NSC-107392), with special reference to its Fe chelating properties. Cancer Chemother Rep. 1974;53:207-212.
37. Richardson DR. Iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol. 1997;75:1164-1180.
38. Bottomley SS, Wolfe LC, Bridges KR. Iron metabolism in K562 erythroleukemia cells. J Biol Chem. 1985;260:6811-6815.
39. Blatt J. Deferoxamine in children with recurrent neuroblastoma. Anticancer Res. 1994;14:2109-2112.
40. Selig RA, White L, Gramacho C, Sterlinglevis K, Fraser IW, Naidoo D. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res. 1998;58:473-478.
41. Ponka P, Borova J, Neuwirt J, Fuchs O. Mobilization of iron from reticulocytes: identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 1997;97:317-321.
42. Ponka P, Borova J, Neuwirt J, Fuchs O, Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta. 1979;586:278-297.
43. Hershko C, Avramovici-Grisaru S, Link G, Gelfand L, Sarel S. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J Lab Clin Med. 1981;98:99-108.
44. Brittenham GM. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. Semin Hematol. 1990;27:112-116.
45. Darnell G, Richardson DR. The potential of analogues of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents, III: the effect of the ligands on molecular targets involved in proliferation. Blood. 1999;94:781-792.
46. Gao J, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents, IV: the mechanisms involved in inhibiting cell cycle progression. Blood. 2001;98:842-850.
47. WAF1/CIP1, but paradoxically inhibit translation: a potential mechanism of cell cycle dysregulation. Carcinogenesis. 2003;24:1045-1058.
48. Liang SX, Richardson DR. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization, and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis. 2003;24:1601-1614.
49. Hileti D, Panayiotidis P, Hoffbrand AV. Iron chelators induce apoptosis in proliferating cells. Br J Haematol. 1995;89:181-187.
50. Abeysinghe RD, Greene BT, Haynes R, et al. p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis. 2001;22:1607-1614.
51. Greene BT, Thorburn J, Willingham MC, et al. Activation of caspase pathways during iron chelator-mediated apoptosis. J Biol Chem. 2002;277:25568-25575.
52. Lim MLR, Lum M-G, Hansen TM, Roucou X, Nagley P. On the release of cytochrome c from mitochondria during cell death signaling. J Biomed Sci. 2002;9:488-506.
53. Jemmerson R, LaPlante B, Treeful A. Release of intact, monomeric cytochrome c from apoptotic and necrotic cells. Cell Death Differ. 2002;9:538-548.
54. Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med. 2000;29:323-333.
55. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256:42-49.
56. Ul-Haq RU, Wereley JP, Chitambar CR. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp Hematol. 1995;23:428-432.
57. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997;326:1-16.
58. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999;68:383-424.
59. Green DR. Apoptotic pathways: the roads to ruin. Cell. 1998;94:695-698.
60. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269-290.
61. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275:1132-1136.
62. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A. 1998;95:4997-5002.
63. Finch RA, Liu M-C, Cory AH, Cory JG, Sartorelli AC. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul. 1999;39:3-12.
64. Richardson DR, Bernhardt PV. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity. J Biol Inorg Chem. 1999;4:266-273.
65. Bacchi A, Carcelli M, Costa M, Pelagatti P, Pelizzi C, Pelizzi G. Versatile ligand behaviour of phenyl 2-pyridyl ketone benzoyl hydrazone in palladium(II) complexes. J Chem Soc Dalton Trans. 1996;22:4239-4244.
66. Karin M, Mintz B. Receptor-mediated endocytosis of transferrin in totipotent mouse teratocarcinoma cells. J Biol Chem. 1981;256:3245-3252.
67. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
68. Yuan J, Murrell GA, Wei AQ, Wang MX. Apoptosis in rotator cuff tendonopathy. J Orthop Res. 2002;20:1372-1379.
69. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995;184:39-51.
70. Yuan J, Murrell GA, Trickett A, Wang MX. Involvement of cytochrome c release and caspase-3 activation in the oxidative stress-induced apoptosis in human tendon fibroblasts. Biochim Biophys Acta. 2003;1641:35-41.
71. Wang M, Wei AQ, Yuan J, Trickett A, Knoops B, Murrell GAC. Expression and regulation of peroxiredoxin 5 in human osteoarthritis. FEBS Lett. 2002;532:359-362.
72. Duffy KJ, Shaw AN, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules, I: discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. J Med Chem. 2002;45:3573-3575.
73. Ido Y, Muto N, Inada A, et al. Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase-3. Cell Prolif. 1999;32:63-73.
74. Bernhardt PV, Caldwell LM, Chaston TB, Chin P, Richardson DR. Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of the di-2-pyridylketone isonicotinoyl hydrazone (HPKIH) analogues. J Biol Inorg Chem. 2003;8:866-880.
75. Armstrong CM, Bernhardt PV, Chin P, Richardson DR. Structural variations and formation constants of first row transition metal complexes of biologically active aroylhydrazones. Eur J Inorg Chem. 2003;1145-1156.
76. Irving H, Williams RJP. Order of stability of metal complexes. Nature. 1948;162:746-747.
77. Sunderman FW. The influence of zinc on apoptosis. Ann Clin Lab Sci. 1995;25:134-142.
78. Cook SA, Sugden PH, Clerk A. Regulation of Bcl-2 family proteins during development and in response to oxidative stress in cardiac myocytes: association with changes in mitochondrial membrane potential. Circ Res. 1999;85:940-949.
79. Atlante A, Calissano P, Bobba A, Azzariti A, Marra E, Passarella S. Cytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic death. J Biol Chem. 2000;275:37159-37166.
80. Takeyama N, Miki S, Hirakawa A, Tanaka T. Role of the mitochondrial permeability transition and cytochrome c release in hydrogen peroxide-induced apoptosis. Exp Cell Res. 2002;274:16-24.
81. Ueda S, Nakamura H, Masutani H, et al. Redox regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and cytochrome c. J Immunol. 1998;161:6689-6695.
82. Zhao M, Antunes F, Eaton JW, Brunk UT. Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur J Biochem. 2003;270:3778-3786.
83. Muindi JRF, Sinha BK, Myers CE. Hydroxyl radical production and DNA damage induced by anthracycline iron complex. FEBS Lett. 1984;172:226-230.
84. Kim BS, Yoon KH, Oh HM, et al. Involvement of p38 MAP kinase during iron chelator-mediated apoptotic cell death. Cell Immunol. 2002;220:96-106.